BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan H, Mao J, Liu C, Fu H, Guo W, Ding G. Risk of adverse events in advanced hepatocellular carcinoma with immune checkpoint therapy: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2020;44:845-54. [PMID: 32307332 DOI: 10.1016/j.clinre.2020.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]